Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diquafosol vs Rebamipide in Dry Eye Disease
NCT07297316Phase 4Completed
- Sponsor
- Korea University Anam Hospital
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of diquafosol and rebamipide in dry eye disease (DED) (2 arms), sponsored by Korea University Anam Hospital. Primary endpoints: Visual Analog Scale at 30 months, Tear Breakup Time at 30 months and 4 more. Started Oct 2022; status: completed.
02
Drugs
diquafosolrebamipide
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07297316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297316.